Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toxicity of first-line abiraterone versus enzalutamide in metastatic castration-resistant prostate cancer
2017-000099-27Phase 4Completed
- Sponsor
- Department of Urology
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) comparing Abiraterone first-line with Enzalutamide (Xtandi) first-line (2 arms). Started Jan 2017; status: completed.
02
Drugs
enzalutamideabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-000099-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000099-27.